US 12,441,788 B2
Anti-müllerian inhibiting substance antibodies and uses thereof
André Pelegrin, Montpellier (FR); Bruno Robert, Montpellier (FR); Pierre Martineau, Montpellier (FR); Maëva Chauvin, Montpellier (FR); Myriam Chentouf, Montpellier (FR); and Nathalie Di Clemente-Besse, Paris (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); INSTITUT REGIONAL DU CANCER DE MONTPELLIER, Montpellier (FR); UNIVERSITE DE MONTPELLIER, Montpellier (FR); and SORBONNE UNIVERSITE, Paris (FR)
Appl. No. 17/763,746
Filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Paris (FR); INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER, Montpellier (FR); UNIVERSITÉ DE MONTPELLIER, Montpellier (FR); and SORBONNE UNIVERSITÉ, Paris (FR)
PCT Filed Sep. 25, 2020, PCT No. PCT/EP2020/076947
§ 371(c)(1), (2) Date Mar. 25, 2022,
PCT Pub. No. WO2021/058763, PCT Pub. Date Apr. 1, 2021.
Claims priority of application No. 19306213 (EP), filed on Sep. 27, 2019.
Prior Publication US 2022/0324962 A1, Oct. 13, 2022
Int. Cl. C07K 16/26 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/26 (2013.01) [A61P 35/00 (2018.01); C07K 2317/21 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01)] 12 Claims
OG exemplary drawing
 
1. An isolated anti-müllerian inhibiting substance (MIS) antibody comprising: (a) a heavy chain wherein the variable domain comprises the H-CDR1 of SEQ ID NO: 1; the H-CDR2 of SEQ ID NO: 2 or SEQ ID NO: 3; the H-CDR3 of SEQ ID NO: 4; and (b) a light chain wherein the variable domain comprises the L-CDR1 of SEQ ID NO: 5; the L-CDR2 of SEQ ID NO: 6; the L-CDR3 of SEQ ID NO: 7.